JP2013514986A - 血液癌の処置方法 - Google Patents

血液癌の処置方法 Download PDF

Info

Publication number
JP2013514986A
JP2013514986A JP2012544869A JP2012544869A JP2013514986A JP 2013514986 A JP2013514986 A JP 2013514986A JP 2012544869 A JP2012544869 A JP 2012544869A JP 2012544869 A JP2012544869 A JP 2012544869A JP 2013514986 A JP2013514986 A JP 2013514986A
Authority
JP
Japan
Prior art keywords
phenyl
dimethoxy
combination
phenylamino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514986A5 (https=
Inventor
カポニグロ，ジョルダーノ
ポルタ，ダイアナ グラウス
ヤオ，ヤオ
グアニャーノ，ヴィト
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013514986A publication Critical patent/JP2013514986A/ja
Publication of JP2013514986A5 publication Critical patent/JP2013514986A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012544869A 2009-12-18 2010-12-17 血液癌の処置方法 Pending JP2013514986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28783109P 2009-12-18 2009-12-18
US61/287,831 2009-12-18
PCT/US2010/060956 WO2011075620A1 (en) 2009-12-18 2010-12-17 Method for treating haematological cancers

Publications (2)

Publication Number Publication Date
JP2013514986A true JP2013514986A (ja) 2013-05-02
JP2013514986A5 JP2013514986A5 (https=) 2014-02-06

Family

ID=43569244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544869A Pending JP2013514986A (ja) 2009-12-18 2010-12-17 血液癌の処置方法

Country Status (4)

Country Link
US (1) US20120258940A1 (https=)
EP (1) EP2512476A1 (https=)
JP (1) JP2013514986A (https=)
WO (1) WO2011075620A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US20150072019A1 (en) 2012-03-30 2015-03-12 Novartis Ag Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CA2952961A1 (en) * 2014-06-25 2015-12-30 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
WO2020168237A1 (en) 2019-02-14 2020-08-20 Bridgene Biosciences, Inc. Fgfr inhibitors for the treatment of cancer
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CA3132348A1 (en) * 2019-04-10 2020-10-15 Dana-Farber Cancer Institute, Inc. Degraders of fibroblast growth factor receptor 2 (fgfr2)
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538989A (ja) * 2002-07-19 2005-12-22 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼの新規インヒビター
WO2007026251A2 (en) * 2005-07-14 2007-03-08 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
JP2009520768A (ja) * 2005-12-21 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体
WO2009133101A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538989A (ja) * 2002-07-19 2005-12-22 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼの新規インヒビター
WO2007026251A2 (en) * 2005-07-14 2007-03-08 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
JP2009520768A (ja) * 2005-12-21 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体
WO2009133101A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5013001972; ＢＩＳＰＩＮＧ　ＧＵＩＤＯ: 'ＢＯＲＴＥＺＯＭＩＢ，ＤＥＸＡＭＥＴＨＡＳＯＮＥ　ＡＮＤ　ＦＩＢＲＯＢＬＡＳＴ　ＧＲＯＷＴＨ　ＦＡＣＴＯＲ　ＲＥＣＥＰＴＯＲ　３-ＳＰＥＣＩＦＩＣ　以下備考' ＣＬＩＮＩＣＡＬ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ１５　Ｎ２, 20090115, Ｐ５２０-５３１ *
JPN6014052439; ｂｌｏｏｄ Ｖｏｌ．　１０５，　Ｎｏ．　７, 2005, ｐ．　２９４１-２９４８ *

Also Published As

Publication number Publication date
WO2011075620A1 (en) 2011-06-23
US20120258940A1 (en) 2012-10-11
EP2512476A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
JP2013514986A (ja) 血液癌の処置方法
Grimaldi et al. MEK inhibitors in the treatment of metastatic melanoma and solid tumors
Tsimberidou Targeted therapy in cancer
Slamon et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
JP7419579B2 (ja) Ｘｅｌｏｘ又はｆｏｌｆｏｘと組み合わせたｔｔフィールドを用いる胃癌の治療
Allen-Petersen et al. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma
AU2019202674B2 (en) Combination therapy for the treatment of cancer
Tanaka et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
JP6742391B2 (ja) 併用療法
Yadav et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Scotlandi et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
Linch et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
Voss et al. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
Schmittel et al. A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer
JP6320379B2 (ja) Ｃｄｋ４／６阻害剤およびｂ−ｒａｆ阻害剤の組合せ医薬
JP2024526155A (ja) Ｅｒｋ１／２およびｓｈｐ２阻害剤の併用療法
Nadal et al. Imatinib mesylate (Gleevec/Glivec) a molecular‐targeted therapy for chronic myeloid leukaemia and other malignancies
Gozgit et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Santoni et al. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
JP2015038110A (ja) Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用
Younes et al. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results
Mita et al. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
CN105338980A (zh) 药物组合
KR20200036880A (ko) 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물
JP2023553532A (ja) 癌の処置のための併用療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512